University Institute of Pathology, Lausanne, Switzerland.
Pathobiology. 2018;85(1-2):18-22. doi: 10.1159/000469664. Epub 2017 May 9.
Although the notion that tumors are heterogeneous is well rooted in diagnostic pathology, the extent of this heterogeneity at the molecular level and its impact on (targeted) treatment choice will certainly influence the practice of pathology. Even though the consequences of tumor heterogeneity for cancer care are as yet incompletely understood, pathologists can contribute to solving major scientific and clinical problems related to tumor heterogeneity by rethinking guidelines for tumor sampling, to have a more comprehensive covering of intratumor heterogeneity in the available tumor tissue samples. They should develop guidelines and/or technology to adequately document sample characteristics such as percentage of tumor cells in a sample. They need to contribute to training of bioinformaticians in the field of cancer pathobiology and integrate such well-trained bioinformaticians in the workflow leading to a final pathology report. They also need to redefine postgraduate training programs in diagnostic pathology to address the need for in-depth training in molecular cancer pathobiology. Pathologists might contribute more to making the public at large aware of the importance of data sharing. Finally, pathologists should support the creation of consortia in which clinical and molecular data are shared with the translational research community.
虽然肿瘤异质性的概念在诊断病理学中已经根深蒂固,但分子水平上这种异质性的程度及其对(靶向)治疗选择的影响肯定会影响病理学的实践。尽管肿瘤异质性对癌症治疗的影响尚未完全被理解,但病理学家可以通过重新思考肿瘤取样指南来为解决与肿瘤异质性相关的重大科学和临床问题做出贡献,以便在可用的肿瘤组织样本中更全面地涵盖肿瘤内异质性。他们应该制定指南和/或技术来充分记录样本特征,例如样本中肿瘤细胞的百分比。他们需要为癌症病理生物学领域的生物信息学家提供培训,并将经过良好培训的生物信息学家整合到导致最终病理报告的工作流程中。他们还需要重新定义诊断病理学的研究生培训计划,以满足深入培训分子癌症病理生物学的需求。病理学家可能会更多地促使公众认识到数据共享的重要性。最后,病理学家应该支持创建联盟,与转化研究界共享临床和分子数据。